Trial Profile
RETURN II: Efficacy and tolerability of subcutaneous interferon beta 1a (REBIF) in patients with relapsing multiple sclerosis following discontinuation of natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RETURN-II
- Sponsors Merck Serono
- 17 Aug 2015 New trial record
- 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.